Case report

An interesting case of small vessel pathology following coronavirus infection

Shadi M Ramadan,1 Eirini V Kasfiki,1 Ciaran WP Kelly,2 Irshad Ali1

SUMMARY
Vasculitis is a descriptive term for a wide variety of conditions characterised by inflammation of the blood vessels that may occur as a primary process or secondary to an underlying disease. Occlusive vasculopathy is a different clinical entity characterised by skin changes and ulceration of the lower extremities because of thrombosis of the small vessels of the dermis and is usually associated with pre-thrombotic conditions. Both conditions can be confirmed or excluded by skin biopsy. We report the case of a 63-year-old woman presenting with upper and lower respiratory tract symptoms followed by a vasculitic rash on both legs. The patient underwent extensive radiological and laboratory investigations that were negative apart from positive coronavirus OC43. A biopsy of the skin was performed. Considering the clinical presentation and the investigations performed, the diagnosis of small vessel vasculopathy following coronavirus OC43 has been suggested by the authors.

BACKGROUND
Numerous microbial agents, including bacteria, viruses, protozoa and fungi, have been described in association with vasculitis.1 This strong causality is well evidenced with certain types of infection such as hepatitis B virus-related polyarteritis nodosa (PAN) and hepatitis C virus-related cryoglobulinaemia,2 3 while this association between infection and vasculitis is less robust with a wide variety of other infectious pathogens. The work-up for vasculitis is, therefore, extensive and aims to exclude other possible aetiologies of malignancy, autoimmune diseases and other infections.

Vasculopathy is associated with risk factors predisposing to thrombosis. Coronaviridae are reported to be associated with thrombotic events.4 This is a case that demonstrates potential association of coronavirus OC43 with vascular pathology that the authors believe is post-immune inflammation, but the diagnosis of vasculopathy has been also suggested by experienced clinicians.

CASE PRESENTATION
A 63-year-old woman presented with a 5-day history of coryza, sore throat, dry cough and vomiting. She developed painful leg swelling and a rash 2 days after the emergence of initial symptoms. She denied mouth ulcers, joint pains or eye symptoms. On further systemic enquiry, she described episodes of visual hallucination, which had fully resolved by the time of hospital attendance, and a couple of self-limiting episodes of epistaxis of no haemodynamic significance. She denied haemoptysis and haematuria, and she felt systemically well. She denied any recent drug ingestion apart from her regular medications, which include mirtazapine and quinine sulphate.

Her medical history was significant for subarachnoid haemorrhage 20 years ago. She stated that she had a similar rash 1 year ago also associated with coryzal symptoms, but in contrast to the current rash, symptoms had resolved spontaneously within 3 days.

Examination revealed purple discoloration of the toes of both feet with non-blanching purpuric lesions on both legs (figure 1). Blisters and haemorrhagic bullae were seen on the medial aspects of both legs and the soles of the feet (figure 2). Both feet were tender and warm to the touch with pedal pulses intact bilaterally and no sensory deficit. Chest, abdominal, cardiac and neurological examinations were normal.

INVESTIGATIONS
Full blood count revealed a mild normocytic, normochromic chronic anaemia (baseline haemoglobin 100×109 g/L), normal total and differential white cell counts and low platelets of 68×109/L. A blood film revealed thrombocytopenia, which gradually normalised during the hospital admission. Coagulation screen remained normal, including activated partial thromboplastin time (APTT),

Figure 1 Image on admission showing purple discoloration of the toes.
prothrombin time (PT) and fibrinogen levels. C reactive protein was mildly elevated (27 mg/L). Renal and liver function, folate and B12 levels were all within normal limits. Urine dipstick was normal.

CT angiography was obtained for whole aorta and bilateral lower limbs, with concurrent CT of the chest, abdomen and pelvis to investigate for arterial thrombus, lymphadenopathy or malignancy. Both scans were normal and excluded mechanical causes for this patient’s presentation.

The patient underwent an extensive vasculitis work-up to further investigate the rash. Autoimmune profile (rheumatoid factor, antineutrophil cytoplasmic antibodies, antinuclear antibodies, anti-dsDNA, chromatin level, lupus anticoagulant antibody, anticardiolipin antibody, anti-Ro antibody, anti-La antibody, anti-Sm antibody, anti-ribonucleoprotein antibody, anti-Jo-1 antibody, ribosomal autoantibody, anticytomegolovirus antibody and extractable nuclear antigen (Scl70 antibody)), complement levels, cryoglobulins, cryofibrinogen, Bence-Jones protein, protein electrophoresis and immunoglobulins were normal (please see Table 1).

Viral screen was only positive for coronavirus OC43. Influenza PCR, hepatitis B and C antibodies, HIV, cytomegalovirus, Epstein-Barr virus and parvovirus B19 serology were all negative. Screening for Legionella, Mycoplasma and Pneumococcus was negative (please see Table 2).

Although the score according to Duke’s criteria was 1, infective endocarditis was excluded by normal echocardiography and serial negative blood cultures. A skin punch biopsy was obtained and demonstrated necrosis in the small vessels with inflammatory cells.

DIFFERENTIAL DIAGNOSIS
The differential diagnosis for this case would be between a vasculitic process and a veno-occlusive vasculopathy.

The initial clinical presentation was typical of a small vessel vasculitic process, but the skin biopsy was taken after steroid initiation and the results were not diagnostic of small vessel vasculitis. A confirmed preceding coronavirus OC43 infection characterised by coryzal symptoms raised the suspicion of a post-viral, ANCA-negative vasculitis. The normalisation of inflammatory markers and thrombocytopenia without any specific intervention lends support to this hypothesis. Extensive negative workup for vasculitis has excluded any other causative pathology.

Vascularopathy is an important differential diagnosis that is sometimes difficult to distinguish from vasculitis. Clinically, the raised palpable purpura was in favour of vasculitis in contrast to the reticular pattern that is usually seen with vasculopathy. Histologically, there was no evidence of vessel wall infiltration to suggest occlusive non-vasculitic vasculopathy. However, in this context, we should acknowledge that differentiation is not always possible because vessel wall infiltration may occur with late occlusive vasculopathy and intravascular thrombosis may complicate vasculitis.

TREATMENT
While in hospital the patient remained systemically well and afebrile, and the respiratory symptoms and the rash on both ankles resolved quickly, the ischaemic changes on the feet worsened daily despite oral calcium channel blockers, intravenous iloprost therapy and sildenafil. Drugs used were oral nifedipine modified release 40 mg two times per day and oral sildenafil 25 mg.

Figure 2  Image on admission showing blisters and haemorrhagic bullae on the medial aspects of the leg.

Table 1  Autoimmune screen

| Investigation                                      | Result                  | Reference range       |
|---------------------------------------------------|-------------------------|-----------------------|
| Rheumatoid factor                                 | <10 IU/mL               | 0–15 IU/mL            |
| Serum antinuclear antibodies (ANA) screen         | Negative                |                       |
| Serum anti-dsDNA                                   | <1 kIU/L                | 0–8 kIU/L             |
| Serum chromatin level                              | <0.2 AI                 | 0.0–0.9 AI            |
| Serum Ro-52 antibody                               | <0.2 AI                 | 0.0–0.9 AI            |
| Serum Ro-60 antibody                               | <0.2 AI                 | 0.0–0.9 AI            |
| Serum La antibody                                  | <0.2 AI                 | 0.0–0.9 AI            |
| Serum Sm IgG antibody                              | <0.2 AI                 | 0.0–0.9 AI            |
| Serum Sm/ribonucleoprotein IgG antibody            | <0.2 AI                 | 0.0–0.9 AI            |
| Serum ribonucleoprotein-A antibody                 | <0.2 AI                 | 0.0–0.9 AI            |
| Serum ribonucleoprotein-68 antibody                | <0.2 AI                 | 0.0–0.9 AI            |
| Serum ribosomal autoantibody screen                | <0.2 AI                 | 0.0–0.9 AI            |
| Serum anti-centromere antibody                     | <0.2 AI                 | 0.0–0.9 AI            |
| Serum extractable nuclear antigen Scl70 antibody  | <0.2 AI                 | 0.0–0.9 AI            |
| Serum Jo-1 antibody                                | <0.2 AI                 | 0.0–0.9 AI            |
| Serum anticycrophilin level                        | 3 GPLU/mL               | 0–19 GPLU/mL          |
| Serum anti-B, glycoprotein-1 antibody level        | <0.2 AI                 | 0.0–0.9 AI            |
| Serum cryoglobulin                                 | No detectable           | After precipitate 7 days |
| Complement C3                                      | 1.6 g/L                 | 0.90–1.80 g/L         |
| Complement C4                                      | 0.32 g/L                | 0.10–0.40 g/L         |
| Serum protein electrophoresis                     | No evidence of          | No evidence of a      |
|                                                    |                         | monoclonal band       |
|                                                    |                         | (paraprotein)          |
| Serum IgG level                                    | 11 g/L                  | 6.0–16.1 g/L          |
| Serum IgA level                                    | 4.0 g/L                 | 0.8–4.0 g/L           |
| Serum IgM level                                    | 1.4 g/L                 | 0.5–2.0 g/L           |
mg three times per day. Iloprost infusions were abandoned after a 3-day trial due to ineffectiveness. The patient presented with pain and was managed with regular paracetamol, codeine and gabapentin with oral morphine for breakthrough pain.

**OUTCOME**

Nine days into admission with no clinical improvement, oral steroids were introduced (prednisolone 30 mg once daily). While the vasculitic rash on the ankles responded well, the steroid therapy did not halt disease progression. The process continued to progress, with the distal parts of the feet becoming more dusky and painful. Fifteen days into admission, the patient’s toes were black and necrotic with no evidence of wet gangrene and were physiologically amputated (figure 3).

**DISCUSSION**

Vasculitis is characterised by inflammation of the blood vessel wall with reactive injury of mural structures, leading to tissue ischaemia and necrosis due to loss of vascular integrity and luminal compromise. Vasculitis may occur as a primary process or may be secondary to another underlying aetiology (eg, infection, drugs and malignancy). Microbes, including bacteria, viruses, protozoa and fungi, have been incriminated in the pathogenesis of vasculitis. The causal link between HCV and viruses and there is well-documented evidence of COVID-19-related vasculitis. Other reported associations between viruses and post-immune vasculitides are less robust and often anecdotal or controversial.

The pathogenesis of most vasculitides caused by viruses is incompletely understood and differs depending on the causative organism. Both direct endothelial invasion and indirect autoimmune mechanisms have been postulated. Coronaviruses (CoVs) are of the Coronaviridae family and are enveloped viruses with a single strand of RNA. Under electron microscopy, the virions appear as spike-like projections from the virus membrane giving the appearance of a crown. Human CoVs (HCoVs) were first described in the 1960s and are now known to comprise a large family of viruses, including 229E, NL63, OC43, HKU1, MERS-CoV, SARS-CoV-1 and SARS-CoV-2 (COVID-19). CoVs predominantly affect the respiratory tract; however, there is evidence linking them to systemic disease. COVID-19 infection has been implicated in the pathogenesis of Kawasaki disease. HCoV-OC43 and HCoV-229E were detected more frequently in brain tissue from multiple sclerosis patients compared with healthy individuals.

Our patient has been exhaustively investigated for known causes of vasculitis. Normal imaging and laboratory investigation has excluded malignancy, and the skin biopsy, although not diagnostic of vasculitis, was taken after steroid initiation and failed to reveal any specific histology, though a vasculitic process could not be excluded. The recent COVID-19 pandemic has revealed the particularly vasculopathic activity of some coronaviruses and there is well-documented evidence of COVID-19-associated vasculitis. Infection, including with viruses known to have strong association with vasculitis such as HCV, HBV and HIV, has also been investigated. The patient had a similar vasculitic rash 1 year ago, but this had been resolved spontaneously and had never been investigated. Therefore, it is difficult to say whether that rash was associated with a similar coronavirus OC43 infection or was related to another pathology. Though we do not have diagnostic histology of vasculitis, we believe this to be a case of small vessel vasculitis caused by coronavirus OC43 infection. Further research is needed to provide more robust evidence for this potential association.
Learning points

► Infection plays an important role as an aetiology or a trigger of certain types of vasculitis and should be included as a part of an extended vasculitis work up.
► Despite being predominantly respiratory tract viruses, coronaviruses have been described in association with other systemic diseases.
► This case suggests a potential association between coronavirus OC43 and small vessel pathology.

Contributors SR: patient consent, data collection and writing the manuscript. EK: contributed in writing the manuscript. CK: contributed in discussion and reference check. IA: proofread the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

REFERENCES

1. Haq SA, Pagnoux C. Infection-Associated vasculitides. *Int J Rheum Dis* 2019;22:109–15.
2. Teng GG, Chatham WW. Vasculitis related to viral and other microbial agents. *Best Pract Res Clin Rheumatol* 2015;29:226–43.
3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference Nomenclature of vasculitides. *Arthritis Rheum* 2013;65:1–11.
4. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. *J Thromb Haemost* 2020;18:1559–61.
5. Llamas-Velasco M, Alegria V, Santos-Briz Ângel, et al. Occlusive Nonvasculitic vasculopathy. *Am J Dermatopathol* 2017;39:637–62.
6. Drerup C, Metze D, Ehrchen J, et al. Evidence for immunoglobulin-mediated vasculitis caused by monoclonal gammopathy in monoclonal gammopathy of unclear significance prompting oncologic treatment. *JAAD Case Rep* 2019;5:288–91.
7. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. *Trends Microbiol* 2016;24:490–502.
8. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020;382:727–33.
9. Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. *J Infect Dis* 2005;191:499–502.
10. Arbour N, Day R, Newcombe J, et al. Neuroinvasion by human respiratory coronaviruses. *J Virol* 2000;74:8913–21.
11. Bouaziz JD, Duong TA, Jachiet M, et al. Vascular skin symptoms in COVID-19: a French observational study. *J Eur Acad Dermatol Venereol* 2020;28.
12. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Transl Res* 2020;220:1–13.

Copyright 2020 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow.